Glucofor-G

Quick links to important sections

Glucofor-G

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucofor-G

Glucofor-G is a prescription-only, fixed-dose combination oral medication used to manage Type 2 diabetes mellitus in adults. It combines two different agents, Glibenclamide (a sulfonylurea) and Metformin Hydrochloride (a biguanide), to provide a dual approach to controlling blood sugar levels.


Glucofor-G: Quick Facts

Property Description
Active Ingredients Glibenclamide, Metformin Hydrochloride
Form Oral Tablet
Pharmacological Class Antidiabetic Combinations (Sulfonylurea/Biguanide)
Common Use Improving glycemic control in Type 2 diabetes
Origin Synthetic

What Type of Antidiabetic Medicine is Glucofor-G?

Glucofor-G is classified as an Antihyperglycemic Combination Drug, indicating it is a single pill that combines two synthetic substances that work to lower blood sugar. It is indicated as an adjunct to diet and exercise for adults with Type 2 diabetes mellitus. This means the medication is intended to be used alongside lifestyle management, often for patients whose condition is not adequately controlled by Metformin or a sulfonylurea alone. The medication is provided for oral administration in the form of a tablet.

Composition: The Glibenclamide and Metformin Combination

The medication's effectiveness stems from its two active ingredients. Glibenclamide belongs to the sulfonylurea class, and Metformin Hydrochloride belongs to the biguanide class, and they function through complementary mechanisms. This combination was developed to address both insulin resistance and beta-cell dysfunction in one treatment. Glibenclamide functions by stimulating the release of the body’s natural insulin, while Metformin Hydrochloride acts primarily by inhibiting the liver's production of excess glucose. This combination strategy offers improved efficacy in specific patient populations.

General Purpose of this Dual-Action Formulation

The general purpose of using this fixed-dose combination is to achieve superior and more stable glycemic control than can be attained by using either Glibenclamide or Metformin Hydrochloride alone. By acting on two different points in the body's sugar regulation pathway, Glucofor-G provides a comprehensive tool for adults whose Type 2 diabetes mellitus requires more intensive management.

What side effects are possible with Glucofor-G?

Glucofor-G's safety profile is defined by officially documented adverse reactions classified by frequency and body system, derived from regulatory sources such as the FDA and EMA. The combination of Glibenclamide and Metformin presents two main, critical safety considerations: the risk of Hypoglycemia (low blood sugar), which is common, and the risk of Lactic Acidosis, a very rare but serious metabolic complication associated with the Metformin component.

Frequency and System-Organ Classes

The most frequently reported effects, categorized as Very Common, are Gastrointestinal disorders (e.g., diarrhea, nausea, vomiting, abdominal pain) and metallic taste. These effects are often described as transient and typically occur at the beginning of treatment.

Adverse reactions are classified across several System-Organ Classes, including Metabolism and Nutrition Disorders, Gastrointestinal Disorders, Nervous System Disorders, and rare effects in the Blood and Lymphatic System (e.g., agranulocytosis) and Hepatobiliary Disorders (e.g., hepatitis).

Serious Adverse Reactions and Restrictions

Lactic Acidosis is the most serious adverse reaction listed, necessitating strict safety restrictions. Use of the medicine is contraindicated in patients with severe renal impairment (kidney function), severe hepatic impairment (liver function), or conditions that predispose to Lactic Acidosis (e.g., acute heart failure, metabolic acidosis, excessive alcohol intake).

Population-specific safety also dictates that assessment of renal function is critical for older adults and individuals with reduced kidney function. Additionally, Vitamin B12 deficiency is a documented risk associated with long-term exposure to Metformin. These restrictions and classifications define the boundaries of the drug’s use as established in regulatory labeling.

Overdose and Emergency Response

Glucofor-G Overdose and when to seek help

The official overdose profile for Glucofor-G is structured around the severe risks posed by its two active components: severe Hypoglycemia from Glibenclamide and life-threatening Lactic Acidosis from Metformin.

Feature Documented Regulatory Description
Documented Manifestations Overdose may present with severe Hypoglycemia (low blood sugar). Lactic Acidosis symptoms can be nonspecific, including malaise, muscle aches, respiratory distress, drowsiness, and abdominal pain.
Physiological Risks Adverse effects involve the metabolic system, potentially leading to cardiovascular issues such as hypotension and neurological changes. Life-threatening outcomes include fatal Lactic Acidosis.
Population Risks The risk of Lactic Acidosis is heightened in individuals with renal impairment and in those age 65 years or greater, as stated in regulatory documents.

Emergency-Response Statements

Classification Aspect Regulatory Mandate
Immediate Action Required The drug must be immediately discontinued if Lactic Acidosis is suspected.
Urgent Medical Care Urgent hospital intervention is required to institute general supportive measures and to perform prompt hemodialysis, which is the recommended procedural intervention for severe Lactic Acidosis.

Regulatory documentation defines the Glucofor-G overdose profile by requiring specific, urgent actions based on these severe risks. Because Lactic Acidosis is a highly severe outcome, the official instructions mandate that urgent medical attention be sought immediately to manage this life-threatening complication, which includes specialized procedures to clear the drug. No specific antidotes are known for the Metformin component.

Therapeutic Uses of Glucofor-G

What Glucofor-G Treats: Main Uses and Benefits

The primary therapeutic use of this dual-agent formulation is as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. The medication is used for patients with conditions marked by increased physiological stress due to inadequate glycemic control.

This formulation is applied across therapeutic domains involving symptoms related to systemic imbalance, specifically addressing high Fasting Plasma Glucose and Postprandial Glucose readings. This makes it relevant for conditions characterized by periods of heightened symptoms where additional management is appropriate. The primary focus is supporting the goal of achieving more consistent metabolic control, which contributes to easing the overall symptom load and plays a role in managing factors that may affect functional stability related to long-term health. The formulation helps address symptom clusters that may become intense or disruptive due to metabolic imbalance.


Quick Fact: Relief for Unstable Blood Sugar

Property Benefit Focus
Primary Indication Inadequate glycemic control in adults with Type 2 diabetes mellitus
Symptom Management Helps address symptoms related to systemic imbalance, such as fluctuations in blood sugar
Patient Benefit Supports the goal of achieving long-term metabolic stability

Regulatory References

  1. NIH DailyMed label for Glyburide-Metformin

Eligibility and Restrictions for Use

Who can and cannot use Glucofor-G?

Glucofor-G is officially indicated for use only in adults with Type 2 diabetes mellitus whose blood sugar levels are not adequately controlled with a single antidiabetic agent. Eligibility for this fixed-dose combination is strictly defined by regulatory bodies to exclude populations where the risks associated with its components are elevated.

Absolute Contraindications

The medicine must not be used in several specific patient groups. These absolute exclusions include individuals with severe renal impairment (eGFR below 30 mL/min/1.73 m²), hepatic insufficiency, or any form of metabolic acidosis, such as diabetic ketoacidosis. It is also contraindicated in patients with Type 1 diabetes mellitus and those with a known allergy or hypersensitivity to either active ingredient. Due to regulatory status, use is also prohibited during lactation (breastfeeding).

Age and Conditional Restrictions

Glucofor-G is not recommended for use during pregnancy and is contraindicated in pediatric patients as its safety and effectiveness have not been established in children. Use in older adults requires caution and frequent assessment of kidney function. Furthermore, the medication must be temporarily discontinued before major surgical procedures or radiological studies involving the intravascular administration of iodinated contrast agents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Glucofor-G, a combination of Glibenclamide and Metformin Hydrochloride, is based on the documented risks associated with each active component as stated in official regulatory documentation.


Contraindicated and High-Risk Combinations

Regulatory documents formally prohibit co-administration with certain substances. Iodinated contrast agents are contraindicated, necessitating the temporary discontinuation of Glucofor-G at the time of or prior to the radiological procedure and for 48 hours subsequent to the procedure. This is due to the risk of Metformin accumulation leading to lactic acidosis. The systemic antifungal Miconazole and the drug Bosentan are also listed as contraindicated due to the risk of severe hypoglycaemia and reduced glibenclamide exposure, respectively.


Documented Exposure and Pharmacodynamic Effects

Co-administration with the cationic drug Cimetidine is documented to increase the Metformin plasma concentration by inhibiting its renal tubular transport systems, such as OCT transporters. Other cationic drugs are noted to have a similar effect. Substances are also categorized by their effect on blood sugar: Potentiators (e.g., NSAIDs, Sulfonamides) increase the risk of low blood sugar, while Antagonists (e.g., Thiazide diuretics, Corticosteroids) may diminish the drug's intended effect.

Alcohol co-administration is restricted, as excessive intake is associated with an increased risk of lactic acidosis.

Mechanism of Action

Glucofor-G acts through a simultaneous dual mechanism that modulates two primary biological pathways involved in glucose regulation: insulin secretion and glucose production by the liver.

Targeting Pancreatic beta-Cell Function for Insulin Release

This mechanism focuses on Glibenclamide's direct action as an insulin secretagogue. It works by binding to and blocking the SUR1 subunit of the K ATP ion channels on pancreatic beta-cells. This blockade triggers a molecular cascade involving cell membrane depolarization and calcium influx, leading to the exocytosis of stored insulin into the bloodstream. This results in increased systemic insulin levels and increased systemic glucose uptake.


Modulating Hepatic Glucose Output via AMPK Activation

This mechanism is driven by Metformin's central action in the liver, where it mildly inhibits Mitochondrial Respiratory Chain Complex I. This inhibition changes the cell's energy ratio ( AMP: ATP), which activates the enzyme AMPK. AMPK activation suppresses key enzyme activity in the Gluconeogenesis pathway, thereby suppressing glucose output by the liver. AMPK also promotes glucose uptake in peripheral tissues, increasing glucose utilization.

Dosage and Administration Information

How to Use Glucofor-G: Official Administration Guidelines

Glucofor-G is a fixed-dose combination of Glibenclamide and Metformin intended for oral administration as a film-coated tablet. The primary instruction for use requires that the medication be taken with meals to optimize gastrointestinal tolerance and help prevent hypoglycemia. Furthermore, each dose must be followed by a meal that contains a sufficiently high carbohydrate content.


Dosing and Titration Protocol

The standard procedure involves initiating therapy with a low dose, such as 1.25 mg/250 mg once or twice daily. For patients switching from monotherapy, the initial dose may be higher, such as 2.5 mg/500 mg twice daily. The dosage should be increased gradually—no sooner than every two weeks—to allow the body to adjust and help avoid gastrointestinal side effects and hypoglycemia. The established maximum daily dose is 20 mg Glibenclamide and 2000 mg Metformin.


Population and Procedural Constraints

Dosing must be carefully adjusted and conservative for older adults due to increased susceptibility to hypoglycemia and the common decline in renal function with age. The use of this combination is contraindicated if the estimated Glomerular Filtration Rate (eGFR) is below 30 mL/min/1.73 m^2, and initiation is generally not recommended if the eGFR is between 30 mL/min/1.73 m^2 and 45 mL/min/1.73 m^2. For certain medical procedures, such as those involving intravascular iodinated contrast media, the medication must be temporarily discontinued and only reinstituted after 48 hours, following re-evaluation of renal function. If a dose is missed, a double dose must not be taken.

Recent Clinical Evidence

Glucofor-G: Recent Clinical Evidence

Evidence in Adults (Initial and Second-Line Use)

Research exploring the combination of Glibenclamide and Metformin primarily involves short-term, randomized controlled trials (RCTs). These studies were designed to evaluate the combination in two main contexts: as an initial treatment for adults whose blood sugar levels were not at goal with diet and exercise alone, and as a treatment for adults whose condition was not at goal with a single medicine (monotherapy).

Trials monitored key biomarkers, including Glycosylated Hemoglobin ( HbA1c) and Fasting Plasma Glucose (FPG), comparing the combination against its two individual components. Findings report the short-term changes in these biomarkers observed with the combination over typical observation periods of 16 to 26 weeks.


Evidence in Specific Patient Groups

Glucofor-G was studied for its use in specific populations, notably children and adolescents (ages 9–16) with Type 2 diabetes. The findings from these pediatric studies were mixed. Studies reported that the trials did not consistently report the same patterns of biomarker change observed in adult populations across all subgroups, and data for other specific comorbidity groups remain insufficient.


Research Gaps and Uncertainties

While some studies were monitored for up to one to two years, the follow-up durations for core trials were limited. This means that the long-term effects on complex outcomes like the prevention of serious complications are not fully established and are largely extrapolated from research on the individual components. Additionally, comparative evidence is lacking for the combination against the full spectrum of newer combination agents available today.

Frequently Asked Questions (FAQ)

Common questions about Glucofor-G (FAQ)


Q: How does Glucofor-G differ from just taking Metformin alone?

Glucofor-G is a fixed-dose combination that provides two different medications, Glibenclamide and Metformin, in a single pill. Official information states that this dual approach is typically used when blood sugar levels are not adequately controlled by Metformin or Glibenclamide alone. The Glibenclamide component works by helping to stimulate the body’s release of insulin, while Metformin helps reduce the liver's production of excess sugar.


Q: How quickly does Glucofor-G start to lower blood sugar levels?

Regulatory information indicates that the components of Glucofor-G reach their maximum concentration in the blood within a few hours after being taken. This suggests the medication begins working shortly after administration. However, the precise time it takes to see a noticeable clinical reduction in blood sugar is not standardized and can vary by individual.


Q: How long does it typically take to see the full effect of Glucofor-G on A1C?

Clinical studies designed to evaluate the effectiveness of this medicine usually monitor key blood sugar markers, like Glycosylated Hemoglobin (HbA1c), over periods of 16 to 26 weeks. This suggests that several months of consistent use are generally needed before the medication's full long-term effect on blood sugar control can be assessed.


Q: Is it normal to experience a headache when first starting Glucofor-G?

Regulatory documents list headache as a reported adverse reaction, though it is generally classified as an uncommon or rare side effect. The most commonly reported side effects when initiating treatment are typically gastrointestinal issues such as diarrhea, nausea, and metallic taste.


Q: Can Glucofor-G interact with common over-the-counter pain relievers?

Official drug information warns that certain types of common pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), can potentially interact with Glucofor-G. This interaction may increase the risk of low blood sugar (hypoglycemia). Patients are generally advised to discuss all over-the-counter medicines with a healthcare provider.


Q: Does Glucofor-G affect my weight—will I gain or lose weight?

Regulatory documents report that weight changes are a possible side effect. The Glibenclamide component, a sulfonylurea, can sometimes be associated with weight gain. The Metformin component is often associated with stable weight or modest weight loss. The overall effect on weight can vary for each person.


Q: Is it safe to take Glucofor-G if I have a pre-existing heart condition?

Official labeling states that Glucofor-G is contraindicated (must not be used) if a patient has acute or unstable heart failure. This is due to the potential increased risk of a serious complication called lactic acidosis. Safety in other chronic heart conditions is determined on an individual basis.


Q: Can Glucofor-G be crushed or chewed, or must it be swallowed whole?

Official instructions for use specify that Glucofor-G tablets should be swallowed whole. Crushing or chewing the tablets is generally advised against because it can potentially alter the way the medicine is absorbed by the body.


Q: How does Glucofor-G help prevent long-term complications of diabetes?

The medicine's official purpose is to improve overall blood sugar control by reducing key biomarkers like HbA1c and Fasting Plasma Glucose. By managing the underlying hyperglycemia (high blood sugar), the medication helps mitigate the long-term risk of associated complications, such as damage to the nerves, kidneys, and blood vessels.


Q: Is it safe for older adults (seniors) to take Glucofor-G?

Glucofor-G can be used by older adults, but regulatory information requires extra caution and conservative dosing in this population. This is due to the increased risk of hypoglycemia and the common age-related decline in kidney function. Official labeling highlights that frequent assessment of kidney function is critical for safe use in this population.


Q: What are the risks of suddenly stopping Glucofor-G without talking to a doctor?

Stopping the use of Glucofor-G would immediately interrupt the medicine’s dual action, which could lead to an uncontrolled rise in blood sugar (hyperglycemia). Regulatory guidance indicates that discontinuing treatment should be done under the supervision of a healthcare professional.


Q: Does Glucofor-G cause issues with iron absorption or anemia?

Regulatory documents explicitly warn about the risk of Vitamin B12 deficiency with long-term use of the Metformin component. This deficiency can sometimes lead to a form of anemia called megaloblastic anemia. There is no specific mention in the official labeling regarding direct issues with iron absorption.


Q: Can Glucofor-G be taken alongside insulin injections?

Regulatory labeling restricts the use of Glucofor-G to being an adjunct to diet and exercise or with other oral agents. Due to the high risk of severe hypoglycemia when combining medicines that stimulate insulin release, the use of this fixed-dose combination alongside insulin injections is a highly individualized decision.


Q: Does Glucofor-G interact with supplements like Vitamin B12?

The Metformin component of Glucofor-G is known to cause a Vitamin B12 deficiency over time. While official documents don't offer specific interaction advice for B12 supplements, management of this deficiency may include appropriate supplementation as guided by a healthcare professional.


Q: Can Glucofor-G make me feel dizzy or unusually tired?

Yes, dizziness is listed as a possible adverse reaction. Furthermore, a common side effect of this medicine is low blood sugar (hypoglycemia), which can often manifest as fatigue, unusual tiredness, or lightheadedness. These effects are reported under Nervous System and Metabolism/Nutrition Disorders.


Q: What happens if Glucofor-G is used by someone without diabetes?

The medicine is strictly indicated only for adults with Type 2 diabetes mellitus. If used by someone who does not have diabetes, the most significant risk is a severe, symptomatic drop in blood sugar (hypoglycemia) due to the strong insulin-releasing action of the Glibenclamide component.


Q: Does Glucofor-G affect fertility or the chance of pregnancy in women?

Official information generally does not address effects on fertility directly. However, the medicine is not recommended during pregnancy and is strictly contraindicated while breastfeeding (lactation), as outlined in the regulatory documents.


Q: Are there different formulations or extended-release versions of Glucofor-G?

Glucofor-G is supplied in specific fixed-dose strengths as a film-coated tablet. The official labeling for this product will detail all available strengths and specify whether the formulation is immediate-release or extended-release.


Q: Are there any specific foods or drinks I should absolutely avoid while taking Glucofor-G?

Official documents place a strong restriction on excessive alcohol consumption because it significantly increases the risk of a serious complication called lactic acidosis. While the medicine must be taken with meals, no specific foods are absolutely prohibited.


Q: Is it possible to develop a rash or hives from taking Glucofor-G?

Yes, skin disorders such as rash, urticaria (hives), and pruritus (itching) are listed in official documents as known adverse reactions, usually classified as rare. Additionally, a known hypersensitivity (allergy) to either component is listed as a contraindication.


Q: Does Glucofor-G cause any changes in vision?

Official documents list transient visual disturbances as a possible side effect, particularly when treatment begins. These changes are generally temporary and may be related to the body adjusting to normalized blood sugar levels.


Q: Do I need to adjust my exercise routine when taking Glucofor-G?

Official warnings note that increased physical exertion can contribute to the risk of low blood sugar (hypoglycemia). While the documents don't offer specific exercise advice, they highlight the importance of balancing activity levels and food intake to prevent blood sugar from dropping too low.


Q: Does taking Glucofor-G mean I no longer need to diet and exercise?

No. Official regulatory documents explicitly state that this medication is indicated only as an adjunct to diet and exercise. Lifestyle modifications, including proper nutrition and physical activity, remain a foundational and necessary part of managing Type 2 diabetes.


Q: Can Glucofor-G cause liver problems or changes in liver function tests?

The medicine is strictly contraindicated for use in patients with severe hepatic (liver) impairment. Official documents also report rare instances of hepatobiliary disorders, including hepatitis and abnormal changes in liver function tests.


Q: Is Glucofor-G known to cause flu-like symptoms or upper respiratory infections?

Official adverse event reports based on clinical trials often include upper respiratory tract infections as a possible side effect, although this is generally not classified among the most common adverse reactions.


Q: Are there any mental side effects like anxiety or mood changes reported with Glucofor-G?

While not listed as a common primary side effect, hypoglycemia (low blood sugar) can cause symptoms that may mimic mood changes, such as irritability, confusion, or anxiety. These effects are generally secondary to the blood sugar drop itself.


Q: Will Glucofor-G interfere with my ability to drive or operate machinery?

Official product information warns that the potential for low blood sugar (hypoglycemia) can cause symptoms like dizziness and impaired concentration. Patients are advised to be aware of their body’s reaction and potential risks before driving or operating machinery.


Q: Does the medicine come out whole in my stool if it's an extended-release form?

If the specific Glucofor-G formulation is an extended-release product, the inactive shell or matrix of the tablet may occasionally pass whole and visible in the stool. This is a recognized process for certain extended-release medications and does not mean the medication itself has failed to be absorbed.


Q: Do I need to carry a source of sugar with me while taking Glucofor-G?

Because Glucofor-G has the potential to cause hypoglycemia (low blood sugar), official regulatory warnings advise patients about the symptoms. For medications that carry the risk of hypoglycemia, patients are generally advised to discuss carrying a source of fast-acting sugar to treat potential symptoms.

How should Glucofor-G be stored and disposed of?

Storage and Disposal Requirements

Glucofor-G (Glibenclamide and Metformin Hydrochloride) must be stored according to regulatory standards to ensure product stability.


Official Storage Conditions

The tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Temporary excursions between 15 C and 30 C (59 F and 86 F) are permitted. The medicine must be protected from light and moisture and kept in a tightly closed, light-resistant container.

Handling and Safety

Containers must be dispensed with a child-resistant closure. It is required to keep Glucofor-G out of the reach of children.

Disposal

Unused or expired Glucofor-G should be disposed of by following local regulations or utilizing a medicine take-back program. Disposal procedures should follow official guidance for non-controlled substances.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucofor-G found in:

A-Z Index: